Hans Ackerman1, Aintzane Ayestaran2, Christopher H O Olola3, Muminatou Jallow4, Tsiri Agbenyega5, Kalifa Bojang6, David J Roberts7, Sanjeev Krishna8, Peter G Kremsner9, Charles R Newton10, Terrie Taylor11, Clarissa Valim12, Climent Casals-Pascual13. 1. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA. Electronic address: hans.ackerman@nih.gov. 2. ISGlobal, Barcelona, Spain; Hospital Clínic i Provincial de Barcelona, Centro de Diagnóstico Biomédico, Universitat de Barcelona, Barcelona, Spain. 3. Severe Malaria in African Children Network, Welcome Trust Research Laboratories, Kilifi, Kenya; International Academies of Emergency Dispatch, Salt Lake City, UT, USA. 4. Medical Research Council Unit, Fajara, The Gambia. 5. Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. 6. Medical Research Council Unit, Fajara, The Gambia; London School of Hygiene & Tropical Medicine, London, UK. 7. Radcliffe Department of Medicine, University of Oxford, National Institute for Health Research Oxford Biomedical Research Centre, and the National Health Service Blood and Transplant, John Radcliffe Hospital, Headington, Oxford, UK. 8. Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection and Immunity, St George's University of London, London, UK. 9. Institute of Tropical Medicine, German Center for Infection Research, University of Tübingen, Tübingen, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon. 10. Kemri-Wellcome Trust Collaborative Programme, Centre for Geographic Medicine Research Programme, Kilifi, Kenya. 11. Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA; Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi. 12. Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, MI, USA; Blantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi; Department of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health, Boston, MA, USA; Department of Global Health, Boston University School of Public Health, Boston, MA, USA. 13. ISGlobal, Barcelona, Spain; Hospital Clínic i Provincial de Barcelona, Centro de Diagnóstico Biomédico, Universitat de Barcelona, Barcelona, Spain; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Abstract
BACKGROUND: Infection with Plasmodium falciparum leads to severe malaria and death in approximately 400 000 children each year in sub-Saharan Africa. Blood transfusion might benefit some patients with malaria but could potentially harm others. The aim of this study was to estimate the association between transfusion and death among children admitted to hospital with P falciparum malaria. METHODS: In this prospective, multicentre observational study, we analysed admissions to six tertiary care hospitals in The Gambia, Malawi, Gabon, Kenya, and Ghana that participated in the Severe Malaria in African Children network. Patients were enrolled if they were younger than 180 months and had a Giemsa-stained thick blood smear that was positive for P falciparum. Blood transfusion (whole blood at a target volume of 20 mL per kg) was administered at the discretion of the responsible physicians who were aware of local and international transfusion guidelines. The primary endpoint was death associated with transfusion, which was estimated using models adjusted for site and disease severity. We also aimed to identify factors associated with the decision to transfuse. The exploratory objective was to estimate optimal haemoglobin transfusion thresholds using generalised additive models. FINDINGS: Between Dec 19, 2000, and March 8, 2005, 26 106 patients were enrolled in the study, 25 893 of whom had their transfusion status recorded and were included in the primary analysis. 8513 (32·8%) patients received a blood transfusion. Patients were followed-up until discharge from hospital for a median of 2 days (IQR 1-4). 405 (4·8%) of 8513 patients who received a transfusion died compared with 689 (4·0%) of 17 380 patients who did not receive a transfusion. Transfusion was associated with decreased odds of death in site-adjusted analysis (odds ratio [OR] 0·82 [95% CI 0·71-0·94]) and after adjusting for the increased disease severity of patients who received a transfusion (0·50 [0·42-0·60]). Severe anaemia, elevated lactate concentration, respiratory distress, and parasite density were associated with greater odds of receiving a transfusion. Among all study participants, transfusion was associated with improved survival when the admission haemoglobin concentration was up to 77 g/L (95% CI 65-110). Among those with impaired consciousness (Blantyre Coma Score ≤4), transfusion was associated with improved survival at haemoglobin concentrations up to 105 g/L (95% CI 71-115). Among those with hyperlactataemia (blood lactate ≥5·0 mmol/L), transfusion was not significantly associated with harm at any haemoglobin concentration-ie, the OR of death comparing transfused versus not transfused was less than 1 at all haemoglobin concentrations (lower bound of the 95% CI for the haemoglobin concentration at which the OR of death equals 1: 90 g/L; no upper bound). INTERPRETATION: Our findings suggest that whole blood transfusion was associated with improved survival among children hospitalised with P falciparum malaria. Among those with impaired consciousness or hyperlactataemia, transfusion was associated with improved survival at haemoglobin concentrations above the currently recommended transfusion threshold. These findings highlight the need to do randomised controlled trials to test higher transfusion thresholds among African children with severe malaria complicated by these factors. FUNDING: US National Institute of Allergy and Infectious Diseases.
BACKGROUND: Infection with Plasmodium falciparum leads to severe malaria and death in approximately 400 000 children each year in sub-Saharan Africa. Blood transfusion might benefit some patients with malaria but could potentially harm others. The aim of this study was to estimate the association between transfusion and death among children admitted to hospital with P falciparum malaria. METHODS: In this prospective, multicentre observational study, we analysed admissions to six tertiary care hospitals in The Gambia, Malawi, Gabon, Kenya, and Ghana that participated in the Severe Malaria in African Children network. Patients were enrolled if they were younger than 180 months and had a Giemsa-stained thick blood smear that was positive for P falciparum. Blood transfusion (whole blood at a target volume of 20 mL per kg) was administered at the discretion of the responsible physicians who were aware of local and international transfusion guidelines. The primary endpoint was death associated with transfusion, which was estimated using models adjusted for site and disease severity. We also aimed to identify factors associated with the decision to transfuse. The exploratory objective was to estimate optimal haemoglobin transfusion thresholds using generalised additive models. FINDINGS: Between Dec 19, 2000, and March 8, 2005, 26 106 patients were enrolled in the study, 25 893 of whom had their transfusion status recorded and were included in the primary analysis. 8513 (32·8%) patients received a blood transfusion. Patients were followed-up until discharge from hospital for a median of 2 days (IQR 1-4). 405 (4·8%) of 8513 patients who received a transfusion died compared with 689 (4·0%) of 17 380 patients who did not receive a transfusion. Transfusion was associated with decreased odds of death in site-adjusted analysis (odds ratio [OR] 0·82 [95% CI 0·71-0·94]) and after adjusting for the increased disease severity of patients who received a transfusion (0·50 [0·42-0·60]). Severe anaemia, elevated lactate concentration, respiratory distress, and parasite density were associated with greater odds of receiving a transfusion. Among all study participants, transfusion was associated with improved survival when the admission haemoglobin concentration was up to 77 g/L (95% CI 65-110). Among those with impaired consciousness (Blantyre Coma Score ≤4), transfusion was associated with improved survival at haemoglobin concentrations up to 105 g/L (95% CI 71-115). Among those with hyperlactataemia (blood lactate ≥5·0 mmol/L), transfusion was not significantly associated with harm at any haemoglobin concentration-ie, the OR of death comparing transfused versus not transfused was less than 1 at all haemoglobin concentrations (lower bound of the 95% CI for the haemoglobin concentration at which the OR of death equals 1: 90 g/L; no upper bound). INTERPRETATION: Our findings suggest that whole blood transfusion was associated with improved survival among children hospitalised with P falciparum malaria. Among those with impaired consciousness or hyperlactataemia, transfusion was associated with improved survival at haemoglobin concentrations above the currently recommended transfusion threshold. These findings highlight the need to do randomised controlled trials to test higher transfusion thresholds among African children with severe malaria complicated by these factors. FUNDING: US National Institute of Allergy and Infectious Diseases.
Authors: J Crawley; C Waruiru; S Mithwani; I Mwangi; W Watkins; D Ouma; P Winstanley; T Peto; K Marsh Journal: Lancet Date: 2000-02-26 Impact factor: 79.321
Authors: Brendan J McMorran; Laura Wieczorski; Karen E Drysdale; Jo-Anne Chan; Hong Ming Huang; Clare Smith; Chalachew Mitiku; James G Beeson; Gaetan Burgio; Simon J Foote Journal: Science Date: 2012-12-07 Impact factor: 47.728
Authors: A Sabchareon; T Burnouf; D Ouattara; P Attanath; H Bouharoun-Tayoun; P Chantavanich; C Foucault; T Chongsuphajaisiddhi; P Druilhe Journal: Am J Trop Med Hyg Date: 1991-09 Impact factor: 2.345
Authors: Tsin W Yeo; Daniel A Lampah; Emiliana Tjitra; Retno Gitawati; Enny Kenangalem; Kim Piera; Donald L Granger; Bert K Lopansri; J Brice Weinberg; Ric N Price; Stephen B Duffull; David S Celermajer; Nicholas M Anstey Journal: J Infect Dis Date: 2009-11-15 Impact factor: 5.226
Authors: Saba Gul; Flavia L Ribeiro-Gomes; Aline S Moreira; Guilherme S Sanches; Fabiana G Conceição; Cláudio Tadeu Daniel-Ribeiro; Hans C Ackerman; Leonardo J M Carvalho Journal: Sci Rep Date: 2021-06-08 Impact factor: 4.379
Authors: Hans Ackerman; Christopher H O Olola; Sanjeev Krishna; David J Roberts; Peter G Kremsner; Charles R Newton; Terrie Taylor; Clarissa Valim; Climent Casals-Pascual Journal: Lancet Haematol Date: 2020-12-22 Impact factor: 30.153
Authors: Diana M Gibb; Kathryn Maitland; A Sarah Walker; Roisin Connon; Elizabeth C George; Peter Olupot-Olupot; Sarah Kiguli; George Chagaluka; Florence Alaroker; Robert O Opoka; Ayub Mpoya; Kevin Walsh; Charles Engoru; Julius Nteziyaremye; Macpherson Mallewa; Neil Kennedy; Margaret Nakuya; Cate Namayanja; Eva Nabawanuka; Tonny Sennyondo; Denis Amorut; C Williams Musika; Imelda Bates; M Boele van Hensbroek; Jennifer A Evans; Sophie Uyoga; Thomas N Williams; Gary Frost Journal: BMC Public Health Date: 2021-07-29 Impact factor: 3.295